Quince Therapeutics, Inc. announced the poster presentation of safety data from its prior Phase 3 ATTeST clinical trial at the 53rd Child Neurology Society Annual Meeting. The data evaluated treatment-emergent adverse events (TEAEs) in patients with Ataxia-Telangiectasia (A-T) treated with EryDex for one year compared to a placebo control.
Key findings from the presentation indicated that adverse events typically associated with prolonged corticosteroid use, such as Cushingoid features, weight gain, hypertension, hirsutism, diabetes, or stunted growth, were rarely reported. This suggests a favorable safety profile for EryDex, which is designed to provide corticosteroid efficacy while mitigating serious adverse events.
Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, stated that these results suggest EryDex may be a promising therapy for A-T patients requiring chronic steroid use. The company is currently enrolling its pivotal Phase 3 NEAT study and expects to report topline results in the fourth quarter of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.